Drugs that contain Bivalirudin

1. List of Angiomax drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7598343 SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same
Jul, 2028

(5 years from now)

US7582727 SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same
Jul, 2028

(5 years from now)

US7582727

(Pediatric)

SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same
Jan, 2029

(5 years from now)

US7598343

(Pediatric)

SANDOZ INC Pharmaceutical formulations of bivalirudin and processes of making the same
Jan, 2029

(5 years from now)

Market Authorisation Date: 15 December, 2000

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ANGIOMAX before it's patent expiration?
More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in